shire map
Select a

Shire Global

Better Health, Brighter Future

Investigator Initiated Research (IIR)

Areas of Interest

Shire provides IIR grants with the intention of improving medical and scientific knowledge through the generation of new or confirmatory scientific and/or clinical information. 

Although Shire may provide IIR grants in a variety of different therapeutic areas and disease states, Shire is more likely to support grants that focus on current “Areas of Interest (AOI)”.

Please find below Shire’s current areas of interest by therapeutic area questions of interest. AOIs are evaluated as needed to address shifts in scientific knowledge and the company strategy.

Areas of Interest

Click on each of the items below for more information


Hereditary Angioedema


  1. Studies to further characterize the real-world clinical effectiveness of lanadelumab, including clinical outcomes of patients newly initiated on lanadelumab or for patients who have previous experience with alternative therapies for HAE
  2. Studies exploring novel efficacy outcomes (e.g., remission) or composite efficacy endpoints (e.g., patient-reported outcomes and biomarkers) in patients with HAE treated with lanadelumab
  3. Studies exploring the potential for lanadelumab to modify the contact system (e.g., changes in trigger sensitivity, sustained control or suppression)
  4. Studies to explore the efficacy of lanadelumab in other conditions where bradykinin or the kallikrein-kinin system may form the pathological basis of disease


  1. Exploring approaches to facilitating diagnosis and decreasing diagnostic delay
  2. Explore the burden of illness and the burden of treatment, including pediatrics
  3. Characterization of non-histaminergic angioedema, including pathophysiology, prodrome, diagnosis and biomarkers



  1. We support research in immunodeficiency, secondary immunodeficiency and neuroimmunology including peripheral neuropathies.

    Areas of research interest include diagnosis, treatment particularly with immunoglobulin, and outcomes.

GI/Internal Medicine

Adrenal Insufficiency

We are not accepting new IIRs in 2019 for this area.

Eosinophilic Esophagitis (EoE)

  1. Pathogenesis
  2. Biomarkers
  3. Epidemiology, diagnosis, clinical response criteria, and qualitative/quantitative management of symptoms
  4. Clinical, behavioral, burden of illness and comorbid conditions


  1. Mineral Homeostasis in NAC
  2. Bone Effects in NAC with SOC and hormonal treatment
  3. Renal Effects in NAC with SOC and hormonal treatment
  4. Cardio and cerebrovascular Effects in NAC with SOC and hormonal treatment
  5. Immune system function in NAC with SOC and hormonal treatment
  6. Qualitative/Quantitative Management of Symptoms/Signs e.g.
  7. Sleep Quality and Quantity in rhPTH(1-84) treated patients
  8. Cognitive and Executive Function Impairments in Hypoparathyroidism
  9. Sub-groups of Hypoparathyroidism (genetic, autoimmune, postsurgical)
  10. Health Economics and Outcomes studies in NAC with SOC and hormonal treatment
  11. Home Serum Calcium Monitoring
  12. In-vivo and in-vitro MOA

Short Bowel Syndrome

  1. Real world use of teduglutide in adult and pediatric SBS-IF
  2. Long Term Efficacy Studies in adult and pediatric SBS-IF patients who have reached enteral autonomy under teduglutide
  3. Real world use of teduglutide evaluating intestinal adaptation in treated vs. untreated pediatric SBS- IF patients
  4. Prevention/avoidance of Intestinal Transplantation in stable SBS-IF chronic PN dependent adult or pediatric patients
  5. Comparison of maintenance treatment regimen in adult or pediatric patients with SBS-IF having reached enteral autonomy
  6. Predictors of intestinal adaptation in SBS adult or pediatric patients
  7. Real world QoL in adult or pediatric SBS-IF treated vs. untreated patients
  8. Real world QoL in adult SBS- IF treated vs. untreated patients by étiology and bowel anatomy types
  9. Borderline/Fragile non-Parenteral Support (PS) Dependent Short Bowel Syndrome (SBS)
  10. Reduction of Output in High Output conditions (stoma or intact Gastro-intestinal Tract)
  11. Enterocutaneous Fistula Healing
  12. Potential Anti-Inflammatory mechanisms of Teduglutide

Inflammatory Bowel Disease

We are not accepting new IIRs in 2019 for this area

Genetic Diseases

Hunter Syndrome

  1. Analyses of natural history of MPSII
  2. Studies involved in the development or evaluation of biomarkers or diagnostic capabilities in MPS II
  3. Studies examining:
    • Impact of early diagnosis, including screening, and treatment start
    • Long term treatment effectiveness of Idursulfase (also retrospective)
    • Early diagnosis of cognitive impairment
    • Neurodevelopmental assessment
    • Standardization of cognitive testing
    • Neuronopathic MPS II Disease course
  4. Genotypes and phenotypes, as well as their correlation, in different geographies

Fabry Disease

  1. Research fostering understanding of inflammation and immunogenicity in Fabry disease
  2. New screening approaches and patient identification ideas in new high risk populations
  3. Studies involved in the development or evaluation of biomarkers or diagnostic capabilities to:
    • Identify high risk populations
    • Facilitate early disease detection
    • Detection of early disease progression
    • Monitor disease progression
    • Predict/measure therapy effectiveness
  4. Genotypes and phenotypes, as well as their correlation, in different geographies

Gaucher Disease

  1. Screening for patients with Gaucher disease. Methodology aligned with evidence based global guidance, such as Delphi Consensus on earlier diagnosis, as well as innovative screening projects of high risk populations
  2. Generation of data on patient reported outcomes (PRO)
  3. Generation of data on the role of Lyso-Gb1 as a novel biomarker
  4. Studies fostering understanding of inflammation and immunogenicity in Gaucher disease
  5. ERT infusion optimization (e.g. rate of administration, location (hospital/home), infusion pumps, etc.) that could have potential positive impact on convenience and patient QoL
  6. Genotypes and phenotypes, as well as their correlation, in different geographies


Hemophilia A

  1. Studies examining the cost efficiency of recombinant Antihemophilic Factor (ADVATE) and PEGylated –recombinant Antihemophilic Factor (ADYNOVATE/ADYNOVI) with or without myPKFiT
  2. Studies examining the relationship between FVIII levels and the occurrence of bleeds at varying physical activity levels with or without the use of the myPKFiT mobile app
  3. Studies to investigate changes in adherence and quality of life (QoL) in patients using recombinant Antihemophilic Factor (ADVATE) myPKFiT and the myPKFiT patient app
  4. Real World Evidence on use of PEGylated -recombinant Antihemophilic Factor (ADYNOVATE/ADYNOVI), an extended half-life rFVIII (EHL rFVIII), in clinical practice with or without myPKFiT (including safety, efficacy, utilization, QoL, adherence, patient satisfaction etc.)
  5. Studies on other non-coagulation effects of Factor VIII
  6. Studies looking at the GOAL-HEM (Goal Attainment Scaling for Life – Hemophilia) as a patient-centered reported outcome measure to monitor clinical progress
  7. Non-clinical studies on Polyethylenglycol (PEG) safety
  8. Role of PEGylated -recombinant Antihemophilic Factor (ADYNOVATE/ADYNOVI) for tolerization or in previously tolerized/partially tolerized patients
  9. Study projects investigating QoL of Hemophilia patients with a focus of congruency/discrepancy of actual vs. desired lifestyle

Hemophilia A and B Inhibitor prevention and management

  1. Pre-clinical and clinical studies examining the care and treatment of persons with inhibitors and the use of Anti-Inhibitor Coagulant Complex to control and prevent bleeding episodes and perioperative management in adults and children as well as its impact on quality of life (QoL).
  2. Studies exploring the potential immunotolerance effect of Anti-Inhibitor Coagulant Complex prophylaxis during Immunotolerance induction (ITI) in hemophilia patients with inhibitors.
  3. Studies examining clinical effectiveness and pharmacoeconomic aspects of using Anti-Inhibitor Coagulant Complex in prophylaxis as well as in ITI.
  4. Studies examining the use of Anti-Inhibitor Coagulant Complex in prophylaxis with low dose regimens: regimens, clinical outcomes, pharmacoeconomic implications, QoL
  5. Studies examining potential correlations between thrombin generation assay (TGA) parameters and clinical outcomes.
  6. Investigations of differences in patient profiles for hemophilia patients with and without inhibitors, and possible correlations with prediction, prevention, eradication and prophylaxis of inhibitors.
  7. Explore whether knowledge from other immunological disease states can be used to develop better management of inhibitor patients.
  8. Investigate safety profile of Anti-Inhibitor Coagulant Complex to identify possible predictors of outcomes.
  9. Investigate the use and cost effectiveness of low dose FVIII ITI with Anti-Inhibitor Coagulant Complex as compared to high dose FVIII ITI alone.
  10. Investigate the use and cost effectiveness of low dose FIX ITI with Anti-Inhibitor Coagulant Complex as compared to high dose FIX ITI alone or with other components
  11. Preclinical and clinical studies examining the interaction between the co-administration of Anti-Inhibitor Coagulant Complex and non-factor replacement therapies: regimens and doses, clinical outcomes, safety (TMAs & TEEs), pharmacoeconomic implications, global assays.
  12. Investigate the use of Anti-Inhibitor Coagulant Complex in other diseases where it is required to reestablish the coagulation cascade (i.e. vitamin K deficiency, reversal of NOACs, hepatopathy, etc.)

OBIZUR - Acquired & Congenital Hemophilia (AHA)

  1. Explore efficacy and safety of recombinant-porcine Antihemophilic Factor in patient subpopulations (i.e. post-partum or patients with specific comorbidities) with AHA
  2. Relationship between treatment effectiveness, FVIII level and anti-pFVIII inhibitor titer in subjects with AHA receiving recombinant-porcine Antihemophilic factor
  3. Development/validation of dosing algorithms for recombinant-porcine Antihemophilic factor, initial and follow-on, when the anti-porcine FVIII titers are unknown.
  4. Relationship between treatment effectiveness and recombinant-porcine Antihemophilic factor dosing in subjects with AHA
  5. Explore the potential use of recombinant-porcine Antihemophilic factor as treatment for breakthrough bleeds in patients treated with non-factor therapies [Emicizumab]
  6. Studies intended to develop flexible and tailored dosing regimens for recombinant-porcine Antihemophilic Factor
  7. Investigate effectiveness, safety and treatment outcomes of the continuous infusion of recombinant-porcine Antihemophilic Factor
  8. Collect long term data on treatment for patients with AHA

Thrombotic Thrombocytopenic Purpura (TTP)

  1. Long-term outcomes and disease progression in TTP (congenital and or/acquired TTP) with current standard of care
  2. Studies of the epidemiology, disease burden, and/or health care utilization of TTP patients
  3. Genotype/phenotype correlations among TTP patients
  4. Correlation of ADAMTS13 levels with outcomes
  5. Investigate effects and adverse events associated with chronic plasma use
  6. Mechanistic investigations into rADAMTS13 and TTP
  7. Interactions of ADAMTS13 with other proteins that might affect clinical outcomes
  8. Understanding the relationship between subclinical events and development of disease-related complications in TTP
  9. Using clinical biomarkers as proxy for on-going development of disease-related complications in TTP

Hemophilia Gene Therapy

  1. Basic science of adeno-associated virus (AAV) vectors
  2. Measures to evaluate outcomes with hemophilia gene therapy (clinical, humanistic, quality of life, economic, biomarkers, etc.)
  3. Immune response and immunosuppression with gene therapy
  4. Strategies to examining dosing in the presence of AAV antibodies

von Willebrand Disease (VWD)

  1. Assessment of efficiency and safety of VWF in Real World Setting
  2. Studies to examine the relationship(s) between the structure of the rVWF molecule and its longer half life and/or evidence to support its clinical efficacy
  3. Role of VWF multimeric forms in the control of angiogenesis (rVWF in angiodysplasia)
  4. Personalization of VWD therapy (genetic, bleed prediction, bleeding assessment tools,..)
  5. Impact of prophylaxis on long term health outcomes
  6. Impact of VWD on Quality of Life and the burden of disease:
    • Management of GI bleeds
    • Long term consequences of joint bleeds
    • Analysis of traumatic bleeds in young adults and children
    • Impact of menorrhagia on QoL
  7. VWF in acquired VWD

Neuro- science

Attention Deficit Hyperactivity Disorder

  1. C&A and Adult ADHD disease management – recognition, & treatment
  2. Functional outcomes research related to optimal and suboptimal treatment
    of ADHD symptoms
  3. Lisdexamfetamine dimesylate in C&A and Adult ADHD and other comorbid
  4. Effectiveness of Lisdexamfetamine dimesylate RWE
  5. Guanfacine use in complex ADHD patients
    • Guanfacine use in combination with stimulants RWE
    • Guanfacine effect on symptoms and functioning in ADHD patients
      across ages RWE
  6. Adherence & persistence to treatment options in ADHD
  7. Role of adjunctive psychotherapy

Binge Eating Disorder

  1. Observational Studies on patient characteristics, comorbidities, treatment
    patterns, outcomes
  2. Role of adjunctive psychotherapy

Ophthal- mology

Dry Eye Disease

  1. Studies to improve the understanding of Dry Eye Disease including diagnosis, risk factors, inflammation/immunopathogenesis
  2. Studies assessing the clinical benefit of lifitegrast in certain subpopulations and/or ocular conditions such as contact lens wear and cataract and refractive surgery
  3. Studies assessing the clinical benefit of lifitegrast on QoL measures, visual function, and long-term outcomes
  4. Studies that advance the understanding of lifitegrast MOA and its effect on (including, but not limited to), biomarkers, mediators, and ocular surface structures
  • Any studies involving the use of lifitegrast in humans can only be considered after registration in country where study would be conducted


Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE